المؤلفون: Jessica Kundapur, Jodie Nimigon-Young

المصدر: Living with Lupus.

مصطلحات موضوعية: Gerontology, Coping (psychology), Chronic condition, Qualitative analysis, business.industry, Medicine, Social media, Medical information, Young adult, business

الوصف: Background Fabulupus is the only book for young adults, written by young adults with lupus. It was published in December 2012 and addresses all areas of lifestyle for an individual with this chronic illness. Methods Qualitative analysis of Facebook and Instagram accounts associated with Fabulupus. Entries were assessed based on number of comments and/or acknowledgements. Results The most popular items include sleep and work balance. Conclusions Young adult lupus patients are most interested in seeking additional resources and information concerning daily life struggles of living with a chronic condition. Social media posts concerning medical information tend to not draw as much attention. We urge researchers to consider these topics as crucial for further investigation, as well as clinicians to have open conversations with their patients on their general coping. For future, it would be of interest to compare with other like-minded social media for young adults with lupus.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::952d3a82036dff3d3b0d37b0409e3559Test
https://doi.org/10.1136/lupus-2018-lsm.115Test

المؤلفون: Paul E. Goss, G. Thomas Budd, Cynthia X. Ma, Pedro E.R. Liedke, George W. Sledge, Vered Stearns, Manuela Rabaglio, Judith-Anne W. Chapman, Matthew J. Ellis, Lois E. Shepherd, Kathleen I. Pritchard, Jessica Kundapur, James N. Ingle, Aurélie Le Maître

مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, Anastrozole, Breast Neoplasms, Kaplan-Meier Estimate, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Nitriles, medicine, Humans, Aromatase, Musculoskeletal System, Aged, Aromatase inhibitor, biology, Vasomotor, business.industry, Proportional hazards model, Aromatase Inhibitors, Common Terminology Criteria for Adverse Events, ORIGINAL REPORTS, Middle Aged, Triazoles, medicine.disease, Surgery, Androstadienes, Vasomotor System, chemistry, Chemotherapy, Adjuvant, Hot Flashes, biology.protein, Female, business, medicine.drug

الوصف: Purpose Treatment-emergent symptoms with adjuvant tamoxifen and aromatase inhibitors (AIs) have been associated with superior recurrence-free survival (RFS). We hypothesized that MA.27 anastrozole- or exemestane-treated patients with new or worsening vasomotor and/or joint symptoms would have improved RFS. Patients and Methods MA.27 randomly assigned 7,576 postmenopausal women with breast cancer to 5 years of anastrozole or exemestane. Patient-reported symptoms were collected using the Common Terminology Criteria for Adverse Events version 3.0 at protocol-specified baseline and 6- and 12-month clinical visits. Symptoms were considered present with either vasomotor and/or joint complaints. Associations between symptoms and baseline patient characteristics were examined with χ2 and Fisher's exact tests. Subsequent effects of new or worsening symptoms on RFS were examined with landmark analyses and stratified univariable and multivariable Cox models. We examined the effects of 3-month symptoms arising from unplanned clinic visits as a result of severe toxicity. Results Patients were assessable if eligible for the MA.27 trial, received some trial therapy, and had no disease recurrence at the end of a symptom assessment period; 96% of patients (n = 7,306 patients) were included at 6 months, and 96% (n = 7,246) were included at 12 months. Thirty-four percent of patients had baseline symptoms. For patients without baseline symptoms, 25% and 52% had new symptoms by 6 and 12 months, respectively. Neither treatment-emergent nor baseline symptoms significantly impacted RFS (P > .10) in patients with or without baseline symptoms. Conclusion In MA.27, anastrozole or exemestane treatment-emergent symptoms were not associated with improved RFS. Women should be supported through treatment and encouraged to remain on their AI regardless of their symptoms.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048c23daceaebdf7939de978a9cebf36Test
https://europepmc.org/articles/PMC4289722Test/

المؤلفون: Matthew J. Ellis, Manuela Rabaglio, JN Ingle, Judy-Anne W. Chapman, A. Le Maitre, GW Sledge, George Thomas Budd, Vered Stearns, Lois E. Shepherd, Cynthia X. Ma, Kathleen I. Pritchard, Paul E. Goss, Jessica Kundapur

المصدر: Journal of Clinical Oncology. 29:525-525

مصطلحات موضوعية: Gynecology, Oncology, Cancer Research, medicine.medical_specialty, Aromatase inhibitor, Vasomotor, medicine.drug_class, business.industry, medicine.medical_treatment, Cancer, Anastrozole, medicine.disease, Interim analysis, chemistry.chemical_compound, Exemestane, chemistry, Internal medicine, medicine, skin and connective tissue diseases, business, Adjuvant, Tamoxifen, medicine.drug

الوصف: 525 Background: New vasomotor or joint symptoms within 3 months of initiating either tamoxifen or anastrozole in the ATAC trial predicted superior recurrence-free survival (RFS). We hypothesized that women treated with anastrozole (A) or exemestane (E) in NCIC CTG Trial MA.27 who developed new or worsening vasomotor or joint symptoms would have improved RFS. There was no evidence of this correlation at the second interim analysis. We now report results by treatment arm from the final analysis. Methods: 7,576 ER+ postmenopausal women with early breast cancer were accrued to MA.27. Final analysis revealed no significant differences between A and E in the primary endpoints, event free or overall survival. We examined the effect of emergent vasomotor and joint symptoms 3 and 12 months following treatment initiation with A and E on subsequent RFS events excluding non-breast cancer deaths. We examined associations of symptoms with patient characteristics using chi-square tests, and associations of early symptom...

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9abc5cef1f40ab04761bb167be062049Test
https://doi.org/10.1200/jco.2011.29.15_suppl.525Test